Related Experiment Video
Updated: Sep 11, 2025
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
A pH-Sensitive Glutathione Responsive Small-Molecule Probe TZ2 Sensitizes Lung Cancer Cells to Chemotherapy by
Changle Zhong1, Minghan Lu1, Guanhao Pan1
1Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Guangxi Key Laboratory of Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin 541004, China.
Abstract:
The tumor microenvironment plays an important role in tumor incidence, metastasis, and chemotherapy resistance. Novel therapeutic strategies targeting the tumor microenvironment have become a research focus in the field of biomedicine. In this study, we developed a smart small-molecule probe, TZ2, featuring pH/GSH dual-responsive characteristics. TZ2 exhibits a unique pH-dependent reaction mechanism: GSH is preferentially covalently modified with maleimide groups in acidic microenvironments (pH < 7), while specifically activating nucleophilic substitutions under alkaline conditions (pH > 7). It is worth noting that TZ2 effectively eliminates intracellular glutathione (GSH) in a time and concentration-dependent manner, demonstrating significant GSH depletion ability in various tumor cell lines. Pharmacodynamic studies have shown that TZ2 not only inhibits the cell cycle by regulating the expression of cell cycle-related proteins, but also effectively suppresses the cloning ability of cancer cells. Furthermore, TZ2 significantly increases the sensitivity of drug-resistant cancer cells to cisplatin. By integrating microenvironment modulation, real-time monitoring, and synergistic therapy, TZ2 provides a novel molecular tool and theoretical basis for tumor theranostics integration.
Insights
A novel smart probe, TZ2, targets the tumor microenvironment by depleting glutathione (GSH). This dual-responsive molecule inhibits cancer cell proliferation and enhances chemotherapy sensitivity, offering a new tool for integrated tumor theranostics.
Area of Science:
- Biomedical science
- Molecular biology
- Cancer research
Background:
- The tumor microenvironment influences cancer progression and treatment resistance.
- Targeting the tumor microenvironment is a key area in biomedical research.
- Developing novel therapeutic strategies is crucial for effective cancer treatment.
Purpose of the Study:
- To develop a smart small-molecule probe, TZ2, with pH/GSH dual-responsive characteristics.
- To investigate the mechanism of TZ2 in modulating the tumor microenvironment.
- To evaluate the therapeutic potential of TZ2 in cancer treatment and theranostics.
Main Methods:
- Development of TZ2, a pH/GSH dual-responsive small-molecule probe.
- Investigation of TZ2's reaction mechanism under different pH conditions.
- Assessment of TZ2's ability to deplete intracellular glutathione (GSH) in tumor cell lines.
- Pharmacodynamic studies on cell cycle regulation, cancer cell cloning, and drug resistance.
Main Results:
- TZ2 exhibits a unique pH-dependent reaction mechanism, modifying GSH in acidic conditions and activating nucleophilic substitutions in alkaline conditions.
- TZ2 effectively depletes intracellular GSH in a time- and concentration-dependent manner across various tumor cell lines.
- TZ2 inhibits cancer cell cycle progression, suppresses cloning ability, and significantly enhances sensitivity to cisplatin in drug-resistant cells.
Conclusions:
- TZ2 serves as a novel molecular tool for modulating the tumor microenvironment.
- TZ2 demonstrates potential for real-time monitoring and synergistic cancer therapy.
- TZ2 provides a theoretical basis for integrating tumor diagnostics and therapeutics (theranostics).
